CCA
TAK icon

Childress Capital Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Childress Capital Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-137
Closed -$2K – 858
2020
Q4 		$2K Buy
+137
New +$2.4K ﹤0.01% 987

Other funds holding TAK

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Childress Capital Advisors's TAK Position: Q1 2021 in Review

Childress Capital Advisors sold out of Takeda Pharmaceutical (TAK) in Q1 2021, closing a stake of 137 shares — an estimated $2K sold.

Childress Capital Advisors first reported a position in TAK in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 316 funds tracked by Wall St. Rank hold TAK as of Q1 2021.

  • Childress Capital Advisors reported no remaining Takeda Pharmaceutical position as of Q1 2021 after selling out during the quarter.
  • Childress Capital Advisors sold 137 Takeda Pharmaceutical shares in Q1 2021, an estimated $2K.
  • Childress Capital Advisors first reported a position in Takeda Pharmaceutical in Q4 2020 and held it in 1 quarter.
  • Childress Capital Advisors's Takeda Pharmaceutical position peaked at $2K in Q4 2020.
  • 316 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2021.

Based on Childress Capital Advisors's 13F filing for Q1 2021, filed 21 May 2021.